Introduction
============

Idiopathic polypoidal choroidal vasculopathy (IPCV) is a choroidal vascular abnormality characterized by sudden visual loss from macular hemorrhage or breakthrough vitreous hemorrhage. Exudation is also common. The condition was often confused with wet age-related macular degeneration until Yannuzzi et al[@b1-opth-7-1373],[@b2-opth-7-1373] described it as a separate entity. Early reports described in Asians and patients of dark skin race showed a female preponderance, a younger age, an association with systemic hypertension, and presentation of orange retinal lesions and subretinal hemorrhagic detachment,[@b3-opth-7-1373],[@b4-opth-7-1373] but to the best of the authors' knowledge, not in Sub-Saharan Africans. This study describes the patterns of presentation in ten patients diagnosed with IPCV in Ibadan, Sub-Saharan Africa.

Materials and methods
=====================

A retrospective review was done of 10 patients seen in the retina clinic at the Department of Ophthalmology, University College Hospital, Ibadan between 2007 and 2012. The retina register was opened in 2007 after subspecialization in the Department of Ophthalmology at this hospital. Case files of patients with a diagnosis of IPCV vasculopathy were retrieved and studied. The diagnosis was based on clinical findings of subretinal orange lesions, retinal pigment epithelial detachments, subretinal hemorrhagic detachments, and exudates in the absence of drusen, as described in previous reports.[@b1-opth-7-1373]--[@b4-opth-7-1373] Information extracted from the case file included patient demographics, presenting complaints, and visual acuity. Others included fundus findings, treatment modalities, and visual outcome at 3 months. The data were analyzed as proportions and percentages.

Results
=======

The results are summarized in [Table 1](#t1-opth-7-1373){ref-type="table"}.

Discussion
==========

Idiopathic polypoidal choroidal vasculopathy was described by Yannuzzi et al in hypertensive African Americans with hemorrhagic retinal pigment epithelial detachment in the absence of drusen.[@b1-opth-7-1373] The present study showed a female preponderance (male to female ratio, 1:4) in the fifth and sixth decades, in keeping with previous reports of younger age than in patients with age-related macular degeneration.[@b4-opth-7-1373]

In a previous report from our center, a total of 768 retinal cases were seen in the hospital over a 3-year period, of which 101 were diagnosed to have age-related macular degeneration, representing 14% of all retinal cases seen. The peak age was at least 60 years, and the male to female ratio was about 2:3. Wet age-related macular degeneration was seen in 40 (40%) of cases. More females presented with wet age-related macular degeneration (26% versus 14%) and the intermediate form, while more males appeared to present with advanced dry age-related macular degeneration (12% versus 5%).[@b5-opth-7-1373]

Sudden visual loss was the commonest presentation in the present study. Bilateral disease occurs in about 70% of the cases. The main findings included breakthrough vitreous hemorrhage, subretinal orange lesions, and hemorrhagic retinal pigment epithelial detachment with subretinal exudates and blood.

The natural course ([Figures 1](#f1-opth-7-1373){ref-type="fig"}, [2](#f2-opth-7-1373){ref-type="fig"}, and [3](#f3-opth-7-1373){ref-type="fig"}) of the disease includes chronic serosanguinous detachment with preservation of vision. Other patients had hemorrhagic foveal detachment or chronic macular degeneration resulting in profound visual loss. The presentation usually is that of sudden visual loss, some ([Figure 2](#f2-opth-7-1373){ref-type="fig"}) with a chronic course, some with recurrences, and 50% with favorable visual outcomes.[@b4-opth-7-1373],[@b6-opth-7-1373]

Idiopathic polypoidal choroidal vasculopathy is characterized by vascular aneurysmal lesions with interconnecting branches of vessels terminating in polyps. These polyps are prone to developing multiple, recurrent, serosanguinous retinal pigment epithelial detachment and neurosensory retinal detachment due to leakage and/or hemorrhage from the abnormal choroidal vascular lesions.[@b1-opth-7-1373],[@b2-opth-7-1373],[@b4-opth-7-1373]

Reported retinal findings include hemorrhagic detachment in about 75% and exudative findings in 25%.[@b6-opth-7-1373] The present study showed hemorrhagic detachment in about 90% of cases, with breakthrough vitreous hemorrhage in 50% of cases.

The diagnosis of IPCV should be suspected in the presence of hemorrhagic or exudative retinal pigment epithelial detachments in the absence of drusen. However, the definitive diagnosis is established using indocyanine green angiography. This demonstrates the branching vascular network originating from choroidal circulation terminating in aneurysmal dilatation. Indocyanine green angiography uses infrared rays, hence its ability to detect the lesion under blood as opposed to fundus fluorescein angiography.[@b7-opth-7-1373] Indocyanine green angiography studies showed two types of aneurysmal dilatation, ie, the solitary lesion and clusters resembling grapes. The latter is associated with recurrent bleeding and a poor visual prognosis.[@b3-opth-7-1373] Indocyanine green angiography and optical coherence tomography are not available in our center, so the diagnosis was based on clinical findings.

Treatment modalities for IPCV include observation for extrafoveal lesions. Thermal laser is suggested for extrafoveal lesions threatening the fovea. Photodynamic therapy has been reported to be effective for subfoveal lesions by causing occlusion of the abnormal choroidal vasculature with improvement in vision.[@b8-opth-7-1373]--[@b14-opth-7-1373] In the present study, vitrectomy was performed to clear breakthrough vitreous hemorrhage with improvement in vision. Intravitreal bevacizumab helped in clearing vitreous hemorrhage and reducing the height of pigment epithelial detachment. Intravitreal bevacizumab has been demonstrated to be beneficial in IPCV.[@b15-opth-7-1373] Two of our patients were referred abroad for photodynamic therapy.

Visual outcome in the present study showed significant improvement in vitrectomized patients with vitreous hemorrhage. Presenting vision of hand motion and light perception improved to vision ranging from counting fingers at one meter to 6/12 after vitrectomy. Intravitreal bevacizumab was administered to five patients and found to stabilize vision.

Conclusion
==========

IPCV is not uncommon in Ibadan, Sub-Saharan Africa. Patients presenting with sudden visual loss, vitreous hemorrhage, retinal pigment epithelial detachment, and subretinal exudation in the absence of drusen, should raise an index of suspicion in ophthalmologists in Sub-Saharan Africa.
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![Idiopathic polypoidal choroidal vasculopathy with chronic subretinal exudate in a 68-year-old woman (patient 1).](opth-7-1373Fig1){#f1-opth-7-1373}

![Fundus findings in patient 8 with idiopathic polypoidal choroidal vasculopathy. Right eye (**A**) with resolved subretinal blood and macular degeneration. (**A**) subretinal orange lesions (medium arrow); The left eye (**B**) shows fresh subretinal hemorrhage (long arrow); and (**C**) retinal pigment epithelial detachment (short arrow). Note the absence of drusen seen in age-related macular degeneration.](opth-7-1373Fig2){#f2-opth-7-1373}

![Patient 10 with idiopathic polypoidal choroidal vasculopathy. Orange subretinal lesion (long arrow) and subretinal exudates (short arrow).](opth-7-1373Fig3){#f3-opth-7-1373}

###### 

Pattern of presentation of idiopathic polypoidal choroidal vasculopathy in Ibadan

  Patient   Age (years)   Gender   Presentation                   Presenting VA (R and L)   Retina signs                                                                      Treatment                  Outcome VA (R and L)
  --------- ------------- -------- ------------------------------ ------------------------- --------------------------------------------------------------------------------- -------------------------- ----------------------
  1         68            F        Sudden visual loss             R, 6/36; L, 6/60          Peripheral exudates, bilateral                                                    --                         R, 6/36; L, 6/60
  2         47            F        Sudden visual loss             R, LP; L, 6/24            VH, bilateral                                                                     R vitrectomy               R, CF; L, HM
  3         47            F        Sudden visual loss             R, HM; L, LP              Unilateral VH                                                                     R, vitrectomy              R, 6/24; L, LP
  4         55            F        Sudden visual loss             R, CF; L, 6/9             VH, RPE detached bilaterally                                                      R, vitrectomy L, Avastin   R, 6/12; L, 6/36
  5         67            F        Sudden visual loss             R, 6/36; L, HM            Bilateral VH, RPE detachment, scarred macula                                      L, Avastin                 R, HM; L, CF
  6         59            M        Sudden visual loss             R, HM; L, NLP             Unilateral VH                                                                     Vitrectomy                 R, CF; L, NLP
  7         63            M        Sudden visual loss             R, HM; L, NLP             Unilateral VH Scar, orange lesion                                                 Vitrectomy PDT             R, CF; L, LP
  8         56            F        Recurrent sudden visual loss   R, HM; L, 6/60            Bilateral RPE detachment, Subretinal hemorrhage. R, macular scar, orange lesion   Bevacizumab PDT            R, CF; L, 6/60
  9         54            F        Sudden visual loss             R, 6/9; L, 6/5            Unilateral extrafoveal orange lesions, hemorrhage, RPE detachment                 Bevacizumab, focal laser   R, 6/9; L, 6/5
  10        63            F        Sudden bilateral visual loss   R, HM; L, CF              Orange lesions, RPE detachment, macular exudates                                  Bevacizumab                R, CF; L, CF

**Abbreviations:** R, right; L, left; HM, hand motion; CF, count fingers; LP, light perception; NLP, nil light perception; PDT, photodynamic therapy; RPE, retinal pigment epithelium; VH, vitreous hemorrhage; VA, visual acuity.
